MRX-5

Inflammatory bowel disease (IBD)

Morria's MFAIDs have shown preclinical efficacy both in vitro and in vivo in both the Dextran Sulfate Sodium (DSS) and Trinitrobenzene sulfonate (TNBSI-based IBD animal models. Both injection and oral administration were effective in animal models.
MRX-5 is an orally-administered drug that will target this lucrative market and its urgent unmet need for a safe and effective chronic treatment for IBD.